Clinical trial
Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer
NCT00470535 · Roswell Park Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00470535 |
|---|---|
| Title | Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer |
| Official title | Phase II Study of Erlotinib (Tarceva®) in Patients With Advanced Pancreatic Adenocarcinoma |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug, Other |
| Interventions | erlotinib hydrochloride, immunohistochemistry staining method, laboratory biomarker analysis |
| Enrollment | 18 |
| Start date | Jan 1, 2007 |
| Primary completion | Jan 1, 2009 |
| Completion | Sep 1, 2010 |
| First posted | May 7, 2007 |
| Last update posted | Feb 23, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: